Clinical Trials Logo

Filter by:
NCT ID: NCT05930704 Recruiting - Osteoporosis Clinical Trials

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women

Start date: July 4, 2023
Phase: Phase 1
Study type: Interventional

The primary objective was to evaluate the safety and tolerability of SHR-2017 after a single subcutaneous (SC) injection in postmenopausal women

NCT ID: NCT05930665 Recruiting - Clinical trials for Pleural Mesothelioma

Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

Cadonilimab, a tetravalent bispecific antibody targeting PD-1 and CTLA-4, is designed to retain the efficacy benefit of combination of PD-1 and CTLA-4 and improve on the safety profile of the combination therapy. The aim of this study is to evaluate the efficacy and safety of cadonilimab in combination with bevacizumab and standard chemotherapy as first Line therapy in unresectable pleural mesothelioma.

NCT ID: NCT05930457 Completed - Clinical trials for Malignant Solid Tumors

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Start date: July 26, 2023
Phase: Phase 1
Study type: Interventional

This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.

NCT ID: NCT05930444 Completed - Eye Diseases Clinical Trials

Multimodal Machine Learning for Auxiliary Diagnosis of Eye Diseases

Start date: July 21, 2023
Phase:
Study type: Observational

With rapid advancements in natural language processing and image processing, there is a growing potential for intelligent diagnosis utilizing chatGPT trained through high-quality ophthalmic consultation. Furthermore, by incorporating patient selfies, eye examination photos, and other image analysis techniques, the diagnostic capabilities can be further enhanced. The multi-center study aims to develop an auxiliary diagnostic program for eye diseases using multimodal machine learning techniques and evaluate its diagnostic efficacy in real-world outpatient clinics.

NCT ID: NCT05930405 Recruiting - Clinical trials for Video-assisted Thoracic Surgery

Effect of the PIEB Versus CEI on the Quality of Postoperative Recovery in Patients Undergoing VATS Lobectomy

Start date: October 1, 2023
Phase: N/A
Study type: Interventional

In recent years, lobectomy under VATS(Video-assisted thoracic surgery,VATS) has gradually emerged, but there is still a proportion of patients with postoperative pain that affects their postoperative recovery. Epidural analgesia (EA) , the gold standard for postoperative analgesia in thoracic surgery, is currently administered in two ways: 1) continuous epidural infusion 2) programmed intermittent epidural bolus. The former is currently the commonly used method of anesthetic infusion, while the latter has been better studied in obstetrics and major abdominal surgery, but is still unclear in thoracic medicine. This paper aims to investigate the impact of both drug delivery methods on the quality of postoperative recovery in patients undergoing lobectomy by VATS.

NCT ID: NCT05930314 Enrolling by invitation - Lupus Nephritis Clinical Trials

CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

Start date: June 19, 2023
Phase: Early Phase 1
Study type: Interventional

Investigator-initiated, single-arm, open-label, single dose clinical study to evaluate the safety and preliminary efficacy of CNCT19 in treatment of patients with refractory systemic lupus erythematosus(SLE) presented with active lupus nephritis or active immune thrombocytopenia.

NCT ID: NCT05930301 Recruiting - Cervical Clinical Trials

RT201(Tumor Antigen-specific Macrophage Tumor Vaccine)

Start date: October 1, 2021
Phase:
Study type: Observational

This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell separation, cell culture and cell reinfusion according to the SOP of Suzhou Ruotai RT201 Cell Therapy. According to the efficacy evaluation criteria set in this clinical study, the included patients will be evaluated and followed up for a long time, and the original data will be saved to provide real and effective clinical data for the safety and efficacy of RT201 tumor single-target individualized clinical treatment.

NCT ID: NCT05930288 Not yet recruiting - Exercise Clinical Trials

The Effect of Preoperative Walking Exercises on the Prognosis of Supratentorial Brain Tumours Patients After Craniotomy

Start date: March 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about in patients with supratentorial brain tumours. The main questions it aims to answer is: Can short-term preoperative walking exercise protect cognitive function in the short term after craniotomy in patients with supratentorial brain tumor and reduce the incidence of surgery-related complications? Participants will be asked to receive general care and regular walking exercises prior to surgery. Researchers will compare patients who receive only general care before surgery to see if preoperative walking exercise has an effect on postoperative prognosis.

NCT ID: NCT05930275 Recruiting - Crohn's Disease Clinical Trials

Study to Assess Speed of Onset and Durability of Effectiveness of Upadacitinib in Adult Participants With Moderate to Severe Crohn's Disease (CD) in Real World Clinical Practice.

UPlift
Start date: February 19, 2024
Phase:
Study type: Observational

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective upadacitinib is in treating moderately to severely active CD in real world. Speed of onset and durability of effectiveness will be assessed. Upadacitinib is a drug approved for the treatment of CD. All study participants will receive upadacitinib as prescribed by their study doctor in accordance with approved local label. Approximately 1200 participants will be enrolled in approximately 230 sites across the world. Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years. There is expected to be no additional burden for participants in this trial. Study visits may be conducted on-site or virtually as per standard of care.

NCT ID: NCT05930262 Completed - Stroke Clinical Trials

Acupuncture Therapy Combined With Breathing Training for Patients With Stroke Complicated

Start date: May 1, 2020
Phase: N/A
Study type: Interventional

The goal of this prospective randomized controlled study is to explore the clinical efficacy of acupuncture therapy combined with breathing training in patients with stroke complicated with pulmonary infection. The intervention group and control group were treated with conventional drug therapy, rehabilitation therapy and breathing training for 2 consecutive weeks. On this basis, the intervention group additionally received acupuncture therapy. To evaluate the clinical efficacy of both groups.